- Patient Education
Patient Education: Idecabtagene Vicleucel (CART Cell Therapy) - Immunotherapy
Updated: Jan 27
Patient Education: Idecabtagene Vicleucel
ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Idecabtagene Vicleucel ( Abecma)
NIH National cancer institute - cancer.gov site info
This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s): Abecma
FDA Approved: Yes
MedlinePlus Information
A lay language summary of important information about this drug that may include the following:
warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.
Information on Abecma website
INTERNATIONAL MYELOMA FOUNDATION:
Understanding ABECMA® (idecabtagene vicleucel)
IMF Understanding Series
IMF Resource Library
Current FDA-Approved Medications for Multiple Myeloma Treatment
HEALTH TREE UNIVERSITY MYELOMA:
All about Abecma (Idecabtagene Vicleucel)
HealthTree University for Multiple Myeloma Lectures
Health Tree University Myeloma Videos
MULTIPLE MYELOMA RESERACH FOUNDATION:
Standard Treatments - (BCMA)-directed personalized immunotherapy Abecma
MMRF Education Programs
MMRF Videos
References ABECMA- idecabtagene vicleucel:
FDA Label Prescribing Information (Revised 03/2021)
Drug Label Information at DAILYMED - NIH-National Library of Medicine
Other Resources
- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -
* Belantamab mafodotin (Withdrawn from United States market)